Compass Pathways accelerates COMP360 TRD launch by 9-12 months; Q3 net loss $137.7M

COMPASS Pathways plc

2025-Q3 EPS reported -$2.09 vs consensus -$0.40 ▼ miss (-425.4%)

Accelerating commercialization readiness by 9-12 months after positive FDA meeting on NDA strategy including potential rolling submission.
COMP006 9-week data and COMP005 26-week data expected Q1 2026; COMP006 26-week data expected early Q3 2026.
Cash $185.9M as of Sept 30, 2025; full-year 2025 net cash used in operations expected $120M-$145M.
Q3 2025 net loss $137.7M ($1.44/share) includes $101.3M non-cash loss on warrant fair value adjustment.
R&D expenses $27.3M in Q3 2025 vs $32.9M in Q3 2024, down due to discontinued discovery programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.